|Articles|June 15, 2002
- BioPharm International-06-01-2002
- Volume 15
- Issue 6
Business Matters: Is a Turnaround in Sight?
Author(s)G. Steven Burrill
by G. Steven Burrill, Burrill & Company After a strong finish in 2001, biotech is back in the dumps.
Advertisement
Articles in this issue
over 23 years ago
Negotiating and Structuring Strategic Alliancesover 23 years ago
Finding Funding in Biotechnology: Keeping the Companies Aliveover 23 years ago
Stem Cells and Xenotransplantation: Ethics, Patents, and Politicsover 23 years ago
Unlocking the Value of R&D: Managing the Risksover 23 years ago
Viewpoint: United Kingdom highlights biomanufacturing capabilitiesover 23 years ago
Inside Washington: Safety, Risk, and Biotechnology Regulationover 23 years ago
Criminal Penalties for Theft of Biological MaterialNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4